Pacira Biosciences
PCRX
Pacira Biosciences (PCRX) - Total debt
Total debt on the balance sheet as of December 2023 : $0.58 B
According to Pacira Biosciences 's latest financial reports the company's total debt is $0.58 B. A company’s total debt is the sum of all current and non-current debts.
Pacira Biosciences - Total debt on balance sheet (from 2010 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $0.58 B | -23.23% |
| 2022-12-31 | $0.76 B | -32.37% |
| 2021-12-31 | $1.12 B | 108.61% |
| 2020-12-31 | $0.54 B | 53.77% |
| 2019-12-31 | $0.35 B | 20.96% |
| 2018-12-31 | $0.29 B | 5.22% |
| 2017-12-31 | $0.27 B | 154.28% |
| 2016-12-31 | $0.10 B | 4.52% |
| 2015-12-31 | $0.10 B | 0.91% |
| 2014-12-31 | $0.10 B | 4.18% |
| 2013-12-31 | $98.96 M | 292.84% |
| 2012-12-31 | $25.19 M | -1.51% |
| 2011-12-31 | $25.57 M | 2.1% |
| 2010-12-31 | $25.05 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Zogenix ZGNX | N/A | N/A | 🇺🇸 USA |
 Recro Pharma
REPH | N/A | N/A | 🇺🇸 USA |
 Omeros Corporation OMER | $0.34 B | -41.83% | 🇺🇸 USA |
 Flexion Therapeutics
FLXN | N/A | N/A | 🇺🇸 USA |
 Heron Therapeutics HRTX | $0.17 B | -69.35% | 🇺🇸 USA |
 Cara Therapeutics
CARA | $6.08 M | -98.96% | 🇺🇸 USA |